老眼治療の世界市場-2023年～2030年

概要

世界の老眼治療市場は、主に普及率の増加と高齢者人口の増加により、近年著しい成長を遂げています。老眼は加齢に伴う自然なものと考えられているため、非常に一般的な視力低下です。

さらに、老眼の永久的な予防法はありませんが、老眼の管理には、眼鏡、コンタクトレンズ、手術、点眼薬、十分な栄養摂取などがあり、これらの製品を使用することで、患者はよりよく見えるようになります。導電性角膜形成術、レーザー支援その場ケラトミレウシス（LASIK）、レーザー支援上皮下角膜切除術（LASEK）、光屈折矯正術（PRK）などの屈折矯正手術は、老眼の矯正に最も一般的に使用されています。

老眼の有病率の増加、革新的な治療法に対する需要の増加、高齢者人口の増加、認知度の向上と教育、治療オプションの技術的進歩が、予測期間にわたって世界の老眼治療市場を牽引すると予想される主な要因です。

ダイナミクス

革新的な治療法に対する需要の増加が老眼治療市場の成長を牽引

老眼の有病率の増加に伴い、眼鏡、コンタクトレンズ、革新的な点眼薬などの進歩のような革新的な治療法に対する需要が継続的に増加しています。多くの研究活動や臨床試験が革新的な治療法のために行われており、FDAの承認もまた、より良い結果を示す承認製品の使用に対する患者の信頼を高めています。

例えば、2023年2月22日、食品医薬品局（FDA）は、成人の老眼治療用の新規矯正点眼薬候補であるCSF-1（塩酸ピロカルピン）の新薬承認申請を受理しました。

低侵襲性または非侵襲性の製品に対する需要は絶えずあり、点眼薬や眼鏡などの製品は低侵襲性を提供しています。多くの製薬会社は、視力を改善する目の自然な能力を利用する点眼薬の開発に注力しています。また、革新的な製品は、患者が日常生活を送れるようにすることで、患者の生活の質を向上させます。

例えば、2022年10月4日、ムンバイを拠点とする製薬会社Entod Pharmaceuticalsは、加齢に伴う近見視力の低下である老眼の数百万人の生活を変える可能性のある目薬の開発の最終段階にあると発表しました。同社はまた、PresVu点眼薬は瞳孔を小さくする目の自然な能力を利用する可能性があるとしています。

高齢者人口の増加も老眼治療市場の成長を促進

老眼は加齢に伴う自然な視力低下であるため、高齢者人口の増加に伴い、老眼治療に対する需要も増加の一途をたどっています。高齢になるにつれて、近くのものに焦点を合わせる目の能力が低下し、物を見つけたり、本を読んだり、電話やノートパソコンのようなデジタル機器を使ったりすることが困難になります。高齢者人口の増加に伴い、老眼の影響を受ける人の数は増加の一途をたどっており、より良い老眼治療の需要がさらに高まっています。

例えば、2023年4月12日、ジョブソン・オプティカル・グループはReview of Presbyopia and The Aging Eyeの立ち上げを発表しました。このデジタル・コンテンツ・プラットフォームは、45歳以上の世代向けの新技術やケア・プロトコルに関する最先端の教育記事やマルチメディアをアイケア専門家に提供することに焦点を当てています。

高齢者人口は増加の一途をたどっており、高齢者特有のニーズを満たすための研究開発活動や臨床試験の需要が高まっています。このことはさらに、高齢者の老眼に対処するために、快適さを向上させ、効果的な治療と診断オプションを提供するために、患者の好みに合わせた眼鏡のような革新的な治療法の開発につながっています。

限られた治療オプションが市場の成長を妨げる

限られた治療オプションしか利用できないため、老眼治療に対するアンメット・メディカル・ニーズが高まっています。このような限られた治療法は、患者の不満足や、患者の嗜好やライフスタイルに合った適切な選択肢のない包括的な治療選択肢をもたらします。患者は自分の好みや快適さに応じて治療を選択したいと思っていますが、このような限られたアンメット治療の選択肢が患者の不満足につながります。

老眼には様々なタイプがあり、目の解剖学的構造、栄養摂取量、ライフスタイル、視力によって個人によって影響が異なります。治療の選択肢が限られていると、患者に合わせて十分にカスタマイズすることができず、その結果、最適な治療結果が得られません。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 革新的な治療法に対する需要の増加
    • 高齢者人口の増加
  • 抑制要因
    • 限られた治療選択肢
  • 機会
    • 治療選択肢の技術的進歩
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 COVID-19分析

第7章 タイプ別

• 初期老眼
• 機能性老眼
• 絶対老眼
• 早期老視
• 夜間老視

第8章 治療法別

• 眼鏡
  • 老眼鏡
  • 遠近両用メガネ
  • 遠近両用メガネ
  • 累進レンズ
  • オフィス用累進レンズ
  • その他
• コンタクトレンズ
  • 遠近両用コンタクトレンズ
  • 多焦点コンタクトレンズ
  • モノビジョンコンタクトレンズ
  • 改良型モノビジョンコンタクトレンズ
• 手術
  • レーシック手術
  • PRK手術
  • SMILE手術
• 点眼薬
• その他

第9章 エンドユーザー別

• 病院
• 眼科クリニック
• 外来手術センター
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Alcon Vision LLC
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• Novartis AG
• Eyenovia
• Johnson and Johnson Pvt Ltd
• Ocuphire Pharma Inc
• Allergan
• Visus Therapeutics
• Ziemer Ophthalmic Systems
• Sun Pharmaceutical Industries Ltd
• F. Hoffmann-La Roche Ltd.

第13章 付録

Overview

The global presbyopia treatment market experiencing significant growth in recent years mainly owing to the increasing prevalence and rising aging population. Presbyopia is a very common vision loss as it is considered a natural part of aging.

Moreover, there is no permanent prevention for presbyopia but the management of presbyopia includes eyeglasses, contact lenses, surgeries, eye drops, and sufficient nutrient intake, by using these products the patients can see better. Refractive surgeries such as conductive keratoplasty, Laser-Assisted In Situ Keratomileusis (LASIK), Laser-Assisted Subepithelial Keratectomy (LASEK), Photorefractive Keratectomy (PRK) are most commonly used for the correction of presbyopia.

Owing to the increasing prevalence of presbyopia, increasing demand for innovative therapeutics, rising aging population, rising awareness and education, and technological advancements in treatment options are the major factors expected to drive the global presbyopia treatment market over the forecast period.

Dynamics

Increasing Demand for Innovative Therapeutics Drives the Growth of the Presbyopia Treatment Market

With the increasing prevalence of presbyopia, there is a continuously increasing demand for innovative therapeutics like advancements in eyeglasses, contact lenses, innovative eye drops, and so on. Many research activities and clinical trials are going on for innovative treatments and the FDA approvals also enhance the trust in patients for the usage of the approved products, which shows better results.

For instance, on February 22, 2023, The Food and Drug Administration (FDA) accepted for review the New Drug Application for CSF-1 (pilocarpine hydrochloride), a novel corrective eye drop candidate, for the treatment of presbyopia in adults.

There is a continuous demand for products that offer a minimally invasive or non-invasive nature, the products such as eye drops, and eyewear offer a minimally invasive nature. Many pharmaceutical companies focus on the development of eye drops to utilize the eye's natural ability to improve vision. The innovative products also improve the patient's quality of life by enabling them to perform daily activities.

For instance, on October 04, 2022, Entod Pharmaceuticals, a Mumbai-based pharmaceutical company announced that it is in the final stages of developing an eye drop that could change the lives of millions with presbyopia, an age-related blurred near vision. The company also claims that PresVu Eye Drops have the potential to utilize the eye's natural ability to reduce its pupil size.

The Rising Aging Population Also Drives the Growth of the Presbyopia Treatment Market

Presbyopia is an age-related natural vision loss, so as the aging population increases there is also a continuous increasing demand for the presbyopia treatment. As people become older, the eye's ability to focus on near objects reduces, leading to difficulties with finding objects, reading books, and using digital devices like phones and laptops. With the increasing aging population, the number of individuals affecting by presbyopia rises continuously, further driving the demand for better presbyopia treatment.

For instance, on April 12, 2023, The Jobson Optical Group announced the launch of Review of Presbyopia and The Aging Eye, a digital content platform focusing on providing eyecare professionals with cutting-edge educational articles and multimedia on new technologies and care protocols for the age 45 + generation.

There is a continuously growing aging population, which prompted the demand for increased research and development activities and clinical trials to fulfill their specific needs. This further led to the development of innovative therapeutics like eyeglasses according to the patient preferences for enhanced comfort and effective treatment and diagnosis options to address presbyopia in older individuals.

Limited Treatment Options Will Hamper the Growth of the Market

The availability of a limited treatment options leads to unmet medical needs for the presbyopia treatment. These limited treatment results in patient unsatisfaction, comprehensive range of treatment options without suitable choices that linked with their preferences and lifestyle. The patients wants to choose the treatment according to their preferences and comfortability, these limited unmet treatment options results in patient dissafisfaction.

Presbyopia has different types and it affects individuals differently based on their eye anatomy, nutrient intake, lifestyle, and visuality. A limited range of treatment options will not allow for sufficient customization according to the patient, this in turn leads to suboptimal treatment outcomes.

Segment Analysis

The global presbyopia treatment market is segmented based on type, treatment, end-user, and region.

The Contact Lenses from the Treatment Segment Accounted for Approximately 45.5% of the Presbyopia Treatment Market Share

The contact lenses are expected to dominate the market share for the better management of presbyopia. Usually, contact lenses offers a non-invasive approach by correcting the presbyopia. Many patients who are suffering from presbyopia prefers this option over surgical interventions due to the absence of appropriate surgical procedures and their associated recovery times. Contact lenses also provides immediate vision and convenience according to the patient usage.

For instance, on September 12, 2022, Johnson & Johnson Vision Care, Inc., a global leader in eye health announced the launch of its newest innovation, ACUVUE OASYS MAX 1-DAY contact lenses and ACUVUE OASYS MAX 1-Day MULTIFOCAL contact lenses for presbyopia. They are designed with an unprecedented combination of new technologies to help meet the needs of digitally intense lifestyles such as TearStable Technology and OptiBlue light filter. TearStable Technology is designed to maximize tear-film stability and lock in moisture for exceptional all-day comfort and the OptiBlue light filter is designed for vision clarity.

Moreover, the contact lenses also provides the flexibility to switch between near and distant vision without needing to constantly switch between different pairs of glasses. This convenience and the flexibility offers benefits to the patients according to the changing lifestyles and they are virtually invisible, offering natural appearance to the users.

Geographical Penetration

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Advanced Healthcare Infrastructure

North America is well known for key market players such as pharmaceutical companies, medical device companies, and many advanced research institutes. The presence of major players leads to innovative product launches, technological advancements, and performing research activities and clinical trials. These encompass the companies to contribute significant launches and advancements for better treatment, resulting in market dominance.

For instance, Bausch and Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced the U.S. launch of Bausch + Lomb INFUSE Multifocal silicone hydrogel (SiHy) daily disposable contact lenses. Featuring a next-generation material infused with ProBalance Technology for all-day comfort and the company's unique 3-Zone Progressive design, the new lens addresses the dynamic vision needs of patients with presbyopia by delivering clear vision with seamless transitions across near, intermediate, and distance vision while helping to minimize contact lens dryness.

Moreover, North America, particularly the United States and Canada is known for its advanced and well-established healthcare infrastructure including hospitals, ophthalmic clinics, ophthalmic stores, and mobile eye clinics for better and enhanced management of presbyopia. The region is also known for its high healthcare expenditure, and favorable reimbursement policies, resulting in the region's largest market share.

Competitive Landscape

The major global players in the presbyopia treatment market include Alcon Vision LLC, Novartis AG, Eyenovia, Johnson and Johnson Pvt Ltd, Ocuphire Pharma Inc, Allergan, Visus Therapeutics, Ziemer Ophthalmic Systems, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd. Among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global presbyopia treatment market. During the pandemic, due to the spreading of the virus, the clinical trials for new presbyopia treatments have been temporarily disrupted and by focussing on COVID-19 related therapeutics, the research activities for presbyopia also faced delays due to safety concerns, restrictions on in-person visits, and shifts in resources towards pandemic-related research.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global presbyopia treatment market. The conflict disrupts supply chains of the presbyopia products such as eyeglasses, contact lenses, and others, it could potentially affect the availability of raw materials, components, or finished products globally. And due to less presence of major players, there is less impact on the global market.

By Type

• Incipient Presbyopia
• Functional Presbyopia
• Absolute Presbyopia
• Premature Presbyopia
• Nocturnal Presbyopia

By Treatment

• Eyeglasses
  • Reading Glasses
  • Bifocals
  • Trifocals
  • Progressives
  • Office Progressives
  • Others

• Contact Lenses
  • Bifocal Contact Lenses
  • Multifocal Contact Lenses
  • Monovision Contact Lenses
  • Modified Monovision Contact Lenses

• Surgeries
  • LASIK Surgery
  • PRK Surgery
  • SMILE Surgery
    • Eye Drops
    • Others

By End-User

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On April 12, 2023, Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye, announced Jehan Tamboowalla joined the company as senior vice president of business development and marketing. At Visus, Mr. Tamboowalla will be responsible for identifying and executing strategic partnerships and collaborations as well as leading commercial activities for assets in clinical development. Jehan's successful record of partnering assets, acquiring novel technologies, and launching ophthalmic medicines provides Visus with the expertise required to deliver on our goal of addressing critical unmet needs in the presbyopia eye drop category and beyond.
• On February 15, 2023, Eyenovia, Inc., a pre-commercial ophthalmic technology company developing the Optejet delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the company has entered into a development collaboration agreement with Taiwan-based Formosa Pharmaceuticals, Inc. The agreement seeks to combine Eyenovia's Optejet dispensing technology with Formosa's unique APNT nanoparticle formulation platform for the potential development of new topical ophthalmic therapeutics that employ the Optejet dispenser.
• On January 17, 2023, Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. This acquisition mainly focuses on cataract and presbyopia management.

Why Purchase the Report?

• To visualize the global presbyopia treatment market segmentation based on type, treatment, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of presbyopia treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global presbyopia treatment market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Demand for Innovative Therapeutics
    • 4.1.1.2. Rising Aging Population
  • 4.1.2. Restraints
    • 4.1.2.1. Limited Treatment Options
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological Advancements in Treatment Options
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Incipient Presbyopia *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Functional Presbyopia
• 7.4. Absolute Presbyopia
• 7.5. Premature Presbyopia
• 7.6. Nocturnal Presbyopia

8. By Treatment

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 8.1.2. Market Attractiveness Index, By Treatment
• 8.2. Eyeglasses *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Reading Glasses
  • 8.2.4. Bifocals
  • 8.2.5. Trifocals
  • 8.2.6. Progressives
  • 8.2.7. Office Progressives
  • 8.2.8. Others
• 8.3. Contact Lenses
  • 8.3.1. Bifocal Contact Lenses
  • 8.3.2. Multifocal Contact Lenses
  • 8.3.3. Monovision Contact Lenses
  • 8.3.4. Modified Monovision Contact Lenses
• 8.4. Surgeries
  • 8.4.1. LASIK Surgery
  • 8.4.2. PRK Surgery
  • 8.4.3. SMILE Surgery
• 8.5. Eye Drops
• 8.6. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Ophthalmic Clinics
• 9.4. Ambulatory Surgical Centers
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Alcon Vision LLC *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Novartis AG
• 12.3. Eyenovia
• 12.4. Johnson and Johnson Pvt Ltd
• 12.5. Ocuphire Pharma Inc
• 12.6. Allergan
• 12.7. Visus Therapeutics
• 12.8. Ziemer Ophthalmic Systems
• 12.9. Sun Pharmaceutical Industries Ltd
• 12.10. F. Hoffmann-La Roche Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us